Christine C Davis1, Amelia Zelnak2, J William Eley3, Daniel A Goldstein4, Jeffrey M Switchenko5, Trevor McKibbin6. 1. Beaufort Memorial Hospital, Beaufort, SC, USA christinecdavis12@gmail.com. 2. Northside Hospital Cancer Institute, Cumming, GA, USA. 3. Emory University School of Medicine, Atlanta, GA, USA. 4. Emory University School of Medicine, Atlanta, GA, USA Rabin Medical Center, Petach Tikvah, Israel. 5. Winship Cancer Institute, Atlanta, GA, USA. 6. AstraZeneca, Atlanta, GA, USA.
Abstract
BACKGROUND: Trastuzumab targets the human epidermal growth factor receptor-2 (HER2). Cardiotoxicity is a potential adverse effect, manifesting as either an asymptomatic decline in left-ventricular ejection fraction or infrequently as largely reversible symptomatic heart failure (HF). Monitoring recommendations differ between product labeling and 2012 guidelines, and the clinical utility of serial cardiac monitoring in patients with metastatic breast cancer remains controversial. OBJECTIVE: The objectives of this study were to describe the frequency of monitoring, incidence of symptomatic or asymptomatic HF, overall effect on treatment, and cost of monitoring for cardiotoxicity. METHODS: We preformed an institutional review board-approved retrospective chart review of breast cancer patients receiving trastuzumab from January 1, 2009, through January 1, 2014, at an academic medical center. RESULTS: Out of 154 treatments, 72% were adjuvant, and 28% were metastatic. In the adjuvant setting, a mean of 4.5 (interquartile range [IQR] = 4-5) echocardiograms (echos) over a mean of 11.5 (IQR = 11-12) months were performed. In the metastatic setting, a mean of 3.1 (IQR = 1-5) echos over a mean of 20.2 (IQR = 9-31) months were performed. Symptomatic HF events occurred in 4 adjuvant (3.6%) and 2 metastatic patients (6.5%); 10 patients (6.5%) had a treatment interruption, with 9 (90%) tolerating restart of trastuzumab. Two patients (1.3%) changed treatment as a result of cardiotoxicity. Using population incidence of HER2-positive breast cancer, $13 million could be saved if monitoring were reduced by 1 echo per patient. CONCLUSIONS: Given the low incidence of clinically significant HF and cost of monitoring, less frequent monitoring may be justified.
BACKGROUND:Trastuzumab targets the human epidermal growth factor receptor-2 (HER2). Cardiotoxicity is a potential adverse effect, manifesting as either an asymptomatic decline in left-ventricular ejection fraction or infrequently as largely reversible symptomatic heart failure (HF). Monitoring recommendations differ between product labeling and 2012 guidelines, and the clinical utility of serial cardiac monitoring in patients with metastatic breast cancer remains controversial. OBJECTIVE: The objectives of this study were to describe the frequency of monitoring, incidence of symptomatic or asymptomatic HF, overall effect on treatment, and cost of monitoring for cardiotoxicity. METHODS: We preformed an institutional review board-approved retrospective chart review of breast cancerpatients receiving trastuzumab from January 1, 2009, through January 1, 2014, at an academic medical center. RESULTS: Out of 154 treatments, 72% were adjuvant, and 28% were metastatic. In the adjuvant setting, a mean of 4.5 (interquartile range [IQR] = 4-5) echocardiograms (echos) over a mean of 11.5 (IQR = 11-12) months were performed. In the metastatic setting, a mean of 3.1 (IQR = 1-5) echos over a mean of 20.2 (IQR = 9-31) months were performed. Symptomatic HF events occurred in 4 adjuvant (3.6%) and 2 metastatic patients (6.5%); 10 patients (6.5%) had a treatment interruption, with 9 (90%) tolerating restart of trastuzumab. Two patients (1.3%) changed treatment as a result of cardiotoxicity. Using population incidence of HER2-positive breast cancer, $13 million could be saved if monitoring were reduced by 1 echo per patient. CONCLUSIONS: Given the low incidence of clinically significant HF and cost of monitoring, less frequent monitoring may be justified.
Authors: John W Tumeh; Susan G Moore; Rachel Shapiro; Christopher R Flowers Journal: Expert Rev Pharmacoecon Outcomes Res Date: 2005-04 Impact factor: 2.217
Authors: G Curigliano; D Cardinale; T Suter; G Plataniotis; E de Azambuja; M T Sandri; C Criscitiello; A Goldhirsch; C Cipolla; F Roila Journal: Ann Oncol Date: 2012-10 Impact factor: 32.976
Authors: Mariana Chavez-MacGregor; Jiangong Niu; Ning Zhang; Linda S Elting; Benjamin D Smith; Jose Banchs; Gabriel N Hortobagyi; Sharon H Giordano Journal: J Clin Oncol Date: 2015-05-11 Impact factor: 44.544
Authors: Edward H Romond; Edith A Perez; John Bryant; Vera J Suman; Charles E Geyer; Nancy E Davidson; Elizabeth Tan-Chiu; Silvana Martino; Soonmyung Paik; Peter A Kaufman; Sandra M Swain; Thomas M Pisansky; Louis Fehrenbacher; Leila A Kutteh; Victor G Vogel; Daniel W Visscher; Greg Yothers; Robert B Jenkins; Ann M Brown; Shaker R Dakhil; Eleftherios P Mamounas; Wilma L Lingle; Pamela M Klein; James N Ingle; Norman Wolmark Journal: N Engl J Med Date: 2005-10-20 Impact factor: 91.245
Authors: Jean-Marc Extra; Eric C Antoine; Anne Vincent-Salomon; Thierry Delozier; Pierre Kerbrat; Anne Bethune-Volters; Jean-Paul Guastalla; Marc Spielmann; Louis Mauriac; Jean-Louis Misset; Daniel Serin; Mario Campone; Christophe Hebert; Céline Remblier; Loïc Bergougnoux; Frank Campana; Moïse Namer Journal: Oncologist Date: 2010-07-29
Authors: A L Jones; M Barlow; P J Barrett-Lee; P A Canney; I M Gilmour; S D Robb; C J Plummer; A M Wardley; M W Verrill Journal: Br J Cancer Date: 2009-03-10 Impact factor: 7.640
Authors: Giuseppe Curigliano; Evandro de Azambuja; Daniel Lenihan; Maria Grazia Calabrò; Daniela Cardinale; Carlo Maria Cipolla Journal: Oncologist Date: 2019-05-07
Authors: Somaira Nowsheen; Paul V Viscuse; Ciara C O'Sullivan; Nicole P Sandhu; Tufia C Haddad; Anne Blaes; Jennifer Klemp; Lara Nhola; Joerg Herrmann; Kathryn J Ruddy Journal: Curr Breast Cancer Rep Date: 2017-07-14
Authors: Nathalie I Bouwer; Agnes Jager; Crista Liesting; Marcel J M Kofflard; Jasper J Brugts; Jos J E M Kitzen; Eric Boersma; Mark-David Levin Journal: Breast Date: 2020-04-16 Impact factor: 4.380